Your browser doesn't support javascript.
loading
Hypersensitivity transfusion reactions to platelet concentrate: a retrospective analysis of the French hemovigilance network.
Mertes, Paul M; Tacquard, Charles; Andreu, Georges; Kientz, Daniel; Gross, Sylvie; Malard, Lucile; Drouet, Christian; Carlier, Monique; Gachet, Christian; Sandid, Imad; Boudjedir, Karim.
Afiliación
  • Mertes PM; Department of Anesthesia and Intensive Care, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Tacquard C; Department of Anesthesia and Intensive Care, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  • Andreu G; Institut National de Transfusion Sanguine, Paris, France.
  • Kientz D; Etablissement Français du Sang Grand Est, Strasbourg, France.
  • Gross S; Etablissement Français du Sang, La Plaine Saint-Denis, France.
  • Malard L; Etablissement Français du Sang, La Plaine Saint-Denis, France.
  • Drouet C; INSERM U1016, CNRS UMR8104, Institut Cochin, Université Paris-Descartes, Paris, France.
  • Carlier M; Agence Régionale de Santé Grand Est, Châlons en Champagne, France.
  • Gachet C; Etablissement Français du Sang Grand Est, Strasbourg, France.
  • Sandid I; French National Agency for Medicines and Health Products Safety (ANSM), Saint Denis, France.
  • Boudjedir K; French National Agency for Medicines and Health Products Safety (ANSM), Saint Denis, France.
Transfusion ; 60(3): 507-512, 2020 03.
Article en En | MEDLINE | ID: mdl-30907010
BACKGROUND: Among labile blood products, platelet concentrates (PCs) are the leading cause of hypersensitivity transfusion reactions (HTRs). These reactions often lead to interruption of PC transfusion and can result in a prolonged transfusion process leading to significant morbidity and use of premedication and close monitoring for patients with a history of allergic transfusion reactions. The French hemovigilance database is one of the largest standardized databases providing information on HTRs following administration of labile blood products. In this study, we analyzed this database to assess the relative risk of HTR for each type of PC. STUDY DESIGN AND METHODS: HTRs following PC transfusion were retrospectively extracted from the e-Fit Hemovigilance database of the French National Agency for Medicines and Health Products Safety (ANSM). Frequencies were calculated using the number of specific PCs transfused. RESULTS: Between 2008 and 2014, the overall estimated incidence of HTRs following PC administration was calculated at 232 HTRs per 100,000 PCs transfused. The rate of HTRs was significantly higher with apheresis PC (337/100,000) than with buffy-coat PC (94/100,000). Platelets in additive solutions (PAS) were associated with a significantly lower frequency of HTRs when compared with PCs in native plasma. Amotosalen/UVA- PCs (APCs and BCPCs) which are always in PAS in France, exhibited the lowest frequency of HTRs when compared with their corresponding PCs in native plasma or in PAS (p < 10-7 in all comparisons). CONCLUSION: Our results showed that the type of PC and its processing may have an impact on the risk of HTR.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Transfusión Sanguínea / Reacción a la Transfusión Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Transfusion Año: 2020 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Transfusión Sanguínea / Reacción a la Transfusión Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Transfusion Año: 2020 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos